Trevi Therapeutics (TRVI) Share-based Compensation (2018 - 2026)

Trevi Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 81.37% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 51.4% YoY), while the FY2025 annual figure was $11.5 million, up 69.12% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.2 million, up from $1.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $2.2 million in Q1 2026, with the low at $501000.0 in Q4 2022.
• The 5-year median for Share-based Compensation is $737000.0 (2022), against an average of $909647.1.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation slumped 30.2% in 2022, then surged 112.64% in 2024.
• Trevi Therapeutics' Share-based Compensation stood at $501000.0 in 2022, then grew by 6.59% to $534000.0 in 2023, then soared by 71.72% to $917000.0 in 2024, then jumped by 47.22% to $1.3 million in 2025, then surged by 62.3% to $2.2 million in 2026.
• Business Quant data shows TRVI's Share-based Compensation at $2.2 million in Q1 2026, $1.3 million in Q4 2025, and $1.2 million in Q3 2025.